1. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Issue 4 (21st March 2021) Authors: Gupta, Vikas; Griesshammer, Martin; Martino, Bruno; Foltz, Lynda; Tavares, Renato; Al-Ali, Haifa Kathrin; Giraldo, Pilar; Guglielmelli, Paola; Lomaia, Elza; Bouard, Catherine; Paley, Carole; Tiwari, Ranjan; Zor, Evren; Raanani, Pia Journal: Leukemia & lymphoma Issue: Volume 62:Issue 4(2021) Page Start: 918 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study. Issue 4 (5th July 2021) Authors: Passamonti, Francesco; Gupta, Vikas; Martino, Bruno; Foltz, Lynda; Zaritskey, Andrey; Al‐Ali, Haifa Kathrin; Tavares, Renato; Maffioli, Margherita; Raanani, Pia; Giraldo, Pilar; Griesshammer, Martin; Guglielmelli, Paola; Bouard, Catherine; Paley, Carole; Tiwari, Ranjan; Vannucchi, Alessandro M. Journal: Hematological oncology Issue: Volume 39:Issue 4(2021) Page Start: 558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Issue 10 (October 2021) Authors: Schuster, Stephen J; Tam, Constantine S; Borchmann, Peter; Worel, Nina; McGuirk, Joseph P; Holte, Harald; Waller, Edmund K; Jaglowski, Samantha; Bishop, Michael R; Damon, Lloyd E; Foley, Stephen Ronan; Westin, Jason R; Fleury, Isabelle; Ho, P Joy; Mielke, Stephan; Teshima, Takanori; Janakiram, Mu... Journal: Lancet oncology Issue: Volume 22:Issue 10(2021) Page Start: 1403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. (4th February 2020) Authors: Al‐Ali, Haifa Kathrin; Griesshammer, Martin; Foltz, Lynda; Palumbo, Giuseppe A.; Martino, Bruno; Palandri, Francesca; Liberati, Anna Marina; le Coutre, Philipp; García‐Hernández, Carmen; Zaritskey, Andrey; Tavares, Renato; Gupta, Vikas; Raanani, Pia; Giraldo, Pilar; Hänel, Mathias; Damiani, Danie... Journal: British journal of haematology Issue: Volume 189:Number 5(2020) Page Start: 888 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. Issue 9 (20th March 2023) Authors: Laetsch, Theodore W.; Maude, Shannon L.; Rives, Susana; Hiramatsu, Hidefumi; Bittencourt, Henrique; Bader, Peter; Baruchel, André; Boyer, Michael; De Moerloose, Barbara; Qayed, Muna; Buechner, Jochen; Pulsipher, Michael A.; Myers, Gary Douglas; Stefanski, Heather E.; Martin, Paul L.; Nemecek, Ene... Journal: Journal of clinical oncology Issue: Volume 41:Issue 9(2023) Page Start: 1664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗